Section Arrow
LBRX.NASDAQ
- LB Pharmaceuticals Inc
Quotes are at least 15-min delayed:2026/04/08 06:48 EDT
Pre Market
Last
 --
-- (--)
Bid
10.17
Ask
40.22
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 25.3
-1.64 (-6.09%)
Day High 
27.34 
Prev. Close
26.94 
1-M High
27.55 
Volume 
186.88K 
Bid
10.17
Ask
40.22
Day Low
25.1 
Open
27.07 
1-M Low
22.48 
Market Cap 
681.56M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 24.5 
20-SMA 24.54 
50-SMA 23.89 
52-W High 27.55 
52-W Low 13.36 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.13/-3.72
Enterprise Value
684.40M
Balance Sheet
Book Value Per Share
10.51
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
QNCXQuince Therapeutics0.163+0.0755+86.29%-- 
Pre Market 0.3906 +0.2276 +139.63%
SILOSilo Pharma0.5302+0.1744+49.02%-- 
Pre Market 0.4898 -0.0404 -7.62%
LNAILunai Bioworks Inc.0.3941+0.1121+39.75%-- 
Pre Market 0.37 -0.0241 -6.12%
CUECue Biopharma0.1882+0.0112+6.33%-- 
Pre Market 0.1882 0 0.00%
TERNTerns Pharmaceuticals52.62-0.16-0.30%-- 
Pre Market 52.5 -0.12 -0.23%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatmentof neuropsychiatric diseases, including schizophrenia.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.